We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review
Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer.
Hematology/oncology Clinics of North America 2018 December
Large-scale genomic studies have demonstrated that ovarian cancer is characterized by frequent genetic and epigenetic alterations of gene members of the homologous recombination repair pathway. Homologous recombination repair deficiency induces genomic instability and hyperdependence on alternative DNA repair mechanisms, and is associated with enhanced sensitivity to double-strand break-inducing agents such as platinum analogues and poly(adenosine diphosphate)-ribose polymerase inhibitors. The authors review the DNA repair pathway alterations that are present in ovarian cancer, and discuss current and emerging therapeutic approaches that target the DNA damage response and repair focusing on chemotherapy and poly(adenosine diphosphate)-ribose polymerase inhibitors.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app